Summary
EIDP, Inc.'s (CTA-PB) 2009 10-K report highlights a global science and innovation leader operating across diverse sectors including agriculture, electronics, chemicals, coatings, materials, and safety. The company faced a challenging 2009, with consolidated net sales down 14% to $26.1 billion due to a 12% volume decline, reflecting the global economic recession. Despite this, the company demonstrated resilience by focusing on productivity improvements, cost reductions, and strategic growth opportunities in emerging markets. The report emphasizes DuPont's commitment to innovation and sustainability, with significant R&D investments aimed at developing solutions for increasing food production, decreasing fossil fuel dependency, and enhancing safety and environmental protection. While the company's diverse business segments showed varied performance, the Pharmaceuticals segment, reliant on patent-expired drugs Cozaar® and Hyzaar®, is expected to see a significant decline in earnings. The company also detailed ongoing efforts to manage risks, including price volatility for raw materials and energy, potential litigation, environmental liabilities, and global economic uncertainties.
Financial Highlights
53 data points| Revenue | $26.11B |
| R&D Expenses | $1.38B |
| SG&A Expenses | $3.44B |
| Operating Expenses | $25.14B |
| Operating Income | $3.34B |
| Interest Expense | $408.00M |
| Net Income | $1.77B |
| EPS (Basic) | $1.93 |
| EPS (Diluted) | $1.92 |
| Shares Outstanding (Basic) | 904.39M |
| Shares Outstanding (Diluted) | 908.71M |
Key Highlights
- 1Consolidated net sales decreased by 14% to $26.1 billion in 2009, driven by a 12% drop in sales volume, largely due to the global economic recession.
- 2DuPont's strategic focus for growth is centered on four key global trends: increasing food production, decreasing dependency on fossil fuels, protecting people and the environment, and growth in emerging markets.
- 3The company is actively managing raw material and energy price volatility through long-term contracts and derivative instruments.
- 4Significant R&D investment continues, with a focus on developing sustainable solutions and innovative products across its diverse business segments.
- 5The Pharmaceuticals segment's income, derived from Cozaar® and Hyzaar®, is projected to decline significantly starting in 2010 due to patent expirations.
- 6DuPont is undertaking substantial restructuring programs aimed at improving long-term competitiveness and aligning costs with market conditions.
- 7The company maintains a strong balance sheet and liquidity position, with $6.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2009.